Skip to main content
OpenTrials

Clinical trial condition

Resectable Skin Lymphoepithelial Carcinoma

Explore clinical trials studying Resectable Skin Lymphoepithelial Carcinoma. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies
Refine in advanced search Browse all conditions

Resectable Skin Lymphoepithelial Carcinoma trial results

Suspended

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

NCT06568172

Conditions
Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma, +17 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Tower Cancer Research Foundation Beverly Hills, California, United States
View all 206 locations
View Trial Details

Related conditions